Design and methods
We isolated phenotypically defined CD4 + T cell subpopulations from circulating lymphocytes of DR52b + healthy donors by flow-cytometry cell sorting and stimulated them in vitro with peptide ESO , autologous APC and IL-2. We assessed the frequency of ESO-specific cells in the cultures by staining with DR52b/ESO tetramers (ESO-tetramers) and TCR repertoire of ESO-tetramer + cells by co-staining with TCR variable beta chain (BV) specific antibodies. We isolated ESO-tetramer + cells by flow-cytometry cell sorting and expanded them with PHA, APC and IL-2 to generate ESO-specific T H lines. We characterized the lines for antigen recognition, by stimulation with ESO peptide or recombinant protein, cytokine production, by intracellular staining using specific antibodies, and alloreactivity, by stimulation with allo-APC.
Results
Using this approach, we could consistently generate ESO-tetramer + -T H lines from conventional CD4 + CD25 -naïve and central memory populations, but not from effector 
Conclusions
In this study, using MHC class II/ESO tetramers, we have implemented an in vitro priming platform allowing the generation of ESO-monospecific polyclonal T H lines from non-immune individuals, an approach that is of potential interest for adoptive cell therapy of patients bearing ESO-expressing cancers. 6 ) and were cultured in the presence of rhIL-2 (100 U/ml; Chiron). Day 12 cultures were incubated with tetramers at a final concentration of 3 mg/ml for 1 h at 37°C and then stained with anti-CD4 mAb and analyzed by flow cytometry. TCR variable β chain (BV) usage by ESO-specific cells was determined by flow cytometry analysis following staining of day 12 cultures with ESO-tetramers and anti-BV2 mAb (Immunotech) as previously described. 28 ESOspecific T cells were isolated from peptide-stimulated cultures by tetramer-guided flow cytometry cell sorting and expanded by stimulation with PHA and irradiated allogeneic PBMC in the presence of IL-2, as previously described. 28 The specificity of the obtained polyclonal T H lines was assessed by tetramer staining and flow cytometry analysis.
Antigen recognition, cytokine production and alloreactivity
For the assessment of their functional avidity, ESO-specific polyclonal T H lines ( 10 4 ) were incubated with JBUSH cells (10 4 ) in the presence of serial dilutions of peptide (DR52b/ESO thereafter) tetramers and anti-CD4 mAb. As illustrated in Figure 1A and summarized in Figure 1B As illustrated in Figure 3B , 
In vitro primed ESO-tetramer + -T H lines secrete IL-2 and effector cytokines and do not recognize allogeneic dendritic cells
To further characterize the ESO-tetramer + -T H lines generated by in vitro priming functionally, we assessed their cytokine secretion profile, by intracellular staining using cytokine-specific mAb, following stimulation with the antigen. Importantly, we
found that large proportions of cells in the ESO-tetramer + -T H lines were able to produce IL-2 in response to stimulation with the antigen, suggesting that the lines could support their own growth ( Figure 5A ). Slightly lower, but significant, proportions shown in Figure 5B , we observed significant recognition of allo-DC only in the presence of the ESO peptide.
Discussion
Recent data encourage exploring the therapeutic potential of ACT using tumor- 33 and it has been shown that DC activated by thymic stromal lymphopoietin stimulate the homeostatic expansion of autologous naïve CD4 + T cells that adopt and maintain a CM phenotype and a polyclonal repertoire. 34 Thus, our interpretation of these data is that ESO-specific Because the specificity of the lines is strictly selected on a single MHC class II allele/peptide complex, their alloreactivity was expected to be limited, although this would need to be confirmed in each case. In support of the limited potential alloreactivity of the in vitro primed ESO-specific lines, we failed to detect significant recognition of DC from DR52b + donors in the absence of antigen. It is noteworthy that a similar approach using allogeneic EBV-specific CTL from donors is currently used to treat patients with EBV + post-transplantation lymphoproliferative disease and has been found to be safe, with very rare occurrence of allo-responses. 41 Even in case a degree of alloreactivity is detected, their use could still be envisaged through the development of appropriate pre-conditioning regimens, as recently shown in the case of "T-bodies", re-directed T cells bearing fusion receptor proteins composed of single chain tumor-specific antibodies linked to the signaling part of the TCR. 42 Together, the results of this study indicate that an ACT approach based of the use of ESO-specific CD4 + T H generated through in vitro priming is feasible and could be applicable to the treatment of large numbers of patients bearing ESO-expressing Figure S1 , and assessed as in 
